EICHORPublic-registry site landscape for NCT04857359, “Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy”, a Parkinson Disease study sponsored by Addex Pharma S.A.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04857359 (registry record) |
| Study title | Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy |
| Official title | Phase 2b/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients With Parkinson's Disease Receiving Levodopa-based Therapy |
| Sponsor | Addex Pharma S.A. |
| Condition(s) | Parkinson Disease; Dyskinesia, Drug-Induced; Dyskinesias |
| Phase | PHASE2 / PHASE3 |
| Listed sites | 41 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT04857359.
Eichor generates a preliminary site-risk snapshot for NCT04857359 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Parkinson Disease trials
More from Addex Pharma S.A.
← Eichor home · All tracked trials · Parkinson Disease studies · Weekly briefs
